Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
1 DNA Way, South San Francisco, CA, 94080, US
Together, they will discover and develop small-molecule medicines using Ventus' ReSOLVE Platform.
By: Rachel Klemovitch
The new facility will increase Roche’s manufacturing capacity and enhance supply chain resilience.
By: Charlie Sternberg
The project will add more than 400 high-wage manufacturing jobs when the site is operational and more than 1,500 construction jobs during site development.
Repertoire will deploy its DECODE platform to generate target discoveries that Genentech will further optimize and translate into new immune medicines.
TNKase is the first stroke medicine approved by the FDA in nearly 30 years.
COUR is eligible for upfront and near-term milestones of $40 million, plus additional milestones that could exceed $900 million.
By: Kristin Brooks
Wadyka most recently served as Global Head of Scientific Communications at Roche/Genentech.
Phase III ALINA study demonstrates Alecensa reduced the risk of disease recurrence or death by 76%.
Phase III study demonstrated that people lived longer when treated with Columvi in combination with gemcitabine and oxaliplatin.
Payment related to progression of a potential first-in-class project targeting an undisclosed GPCR.
By: Anthony Vecchione
The plant's automation is integrated from the plant floor through enterprise-level systems and combined with single-use equipment allowing rapid tech transfer.
Biogen will have no payment obligations and will receive tiered royalties on potential sales of glofitamab in the U.S.
The first bispecific antibody for the eye to treat two leading causes of vision loss.
To research, develop, and commercialize cancer-targeted Allogeneic T-cell therapies.
Strategic collaboration will leverage Scenic Biotech’s disease modifying Cell-Seq platform in deal that could exceed $375M.
By: Contract Pharma
Enter the destination URL
Or link to existing content
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !
